ClinicalTrials.gg
RecruitingNCT06876350WoodcastUpdated Sep 25, 2026

Woodcasting Versus Thermoplast Splint in CMC Arthroplasty

An interventional study of Woodcasting Splint and Control (Standard treatment) in Carpometacarpal (CMC) Joint Arthritis, sponsored by Foundation for Orthopaedic Research and Education. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Foundation for Orthopaedic Research and Education · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2024, registered Mar 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a prospective, randomized, nonblinded trial to evaluate patient preference in splints after having a carpometacarpal arthroplasty.

Read the detailed description

Patients undergoing carpometacarpal arthroplasty will be randomized into the woodcast or thermoplast splint after their surgery to see which is preferred using compliance and surveys.

02

Conditions studied

  • Carpometacarpal (CMC) Joint Arthritis

Keywords

  • Randomized
  • Hand and Upper Extremity
03

In context

Lead sponsor

Foundation for Orthopaedic Research and Education is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 18 years old.
  • Intact Medical Decision Making
  • Eligible for Surgical Intervention
  • Willing to comply with all aspects of the treatment and evaluation schedule over 6 weeks

Exclusion criteria

Exclusion Criteria:

  • Pregnant Women
  • Deemed Unsuitable by Principal Investigator
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Woodcasting Splint

    Woodcasting is an already FDA approved on the market product that is not used a lot so for the purpose of the study we would like to show superior outcomes.

    Other: Woodcasting Splint

  • Active comparator
    Thermoplastic Splint

    Thermoplastic splints is an FDA approved on the market orthrosis that is used by Occupational Therapists which is standard of care for patients that undergo CMC arthroplasty.

    Other: Control (Standard treatment)

Interventions

  • OtherWoodcasting Splint

    This is the experimental group so we could see the outcomes and preference for patients using surveys and compliance scores

  • OtherControl (Standard treatment)

    Thermoplastic splints are standard of care treatment for patients after CMC arthroplasty. We will use the data from this group as the comparator to the experimental group.

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction Score

    The satisfaction survey consists of three questions totaling 15. The minimum value is a 1, while the maximum value is 15. A higher score indicating highest satisfaction.

    Time frame: 6 Weeks

Secondary outcomes

  1. Waste

    Each splint group creates waste for the fabrication and molding for each patient which will be recorded by the clinical research coordinator and weighed out.

    Time frame: 2 Weeks

  2. Splint Satisfaction

    Patient will have three questions totaling 15 with the higher score indicating highest satisfaction.

    Time frame: 6 Weeks

  3. Splint Issues

    A single question will be filled out by patients on a scale of 1-5 with a score of 5 indicating a lot of issues with their splint.

    Time frame: 6 Weeks

07

Study locations

1 of 1 sites recruiting
  • Florida Orthopaedic Institute
    Tampa, Florida 33637, United States
    Recruiting
    • Andy Nguyen, BS · Contactanguyen@foreonline.org · 8139789700
    • Michael Doarn, MD · Principal investigator
    • Alfred Hess, MD · Sub investigator
    • Ronald Mitchell, MD · Sub investigator
08

References and documents

Publications

  • Nguyen T, Hung VT, Hancock JU, Bailey D, Hess AV, Doarn M. Evaluating Patient Compliance With Woodcast and Thermoplast Splints After Thumb Carpometacarpal Arthroplasty: A Randomized Controlled Trial. Hand (N Y). 2026 Feb 8:15589447251415394. doi: 10.1177/15589447251415394. Online ahead of print. PubMed 41656908 ↗

Individual participant data

Plan to share: No — Each participant data will be grouped for each cohort and averaged, so individual participant data is not necessary to perform a data analysis of the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion May 2025 → Dec 2026 and completion Jun 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Oct 3, 2024
Primary completionEst.
Dec 31, 2026was May 2025
CompletionEst.
Dec 30, 2027was Jun 2025
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2025→Dec 31, 2026
Sep 25, 2026
Study completion
Jun 30, 2025→Dec 30, 2027
Sep 25, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41656908 ↗
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41656908 ↗
    Primary completion May 31, 2025→Dec 31, 2026
    Study completion Jun 30, 2025→Dec 30, 2027
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06876350
Lead sponsor
Foundation for Orthopaedic Research and Education
Responsible party
Michael C. Doarn (Principal Investigator, Foundation for Orthopaedic Research and Education) — Principal investigator
First posted
Mar 14, 2025
Start date
Oct 3, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Andy Nguyen, BS
Contact
anguyen@foreonline.org
8139789700 ext. 6837
Deborah Warren, RN
Contact
dwarren@foreonline.org
8139789700
Michael Doarn, MD
principal investigator · Florida Orthopaedic Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion